New drug-like molecule to treat fragile X Syndrome
Friday, September 16, 2011 - 08:30
in Health & Medicine
Researchers at Vanderbilt University Medical Center, in collaboration with Seaside Therapeutics in Cambridge, Mass., have achieved a milestone in the development of a potential new treatment for fragile X syndrome, the most common genetic cause of autism.